Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer

References

• Ben-Mahrez K, Sorokine I, Thierry D, Kawasumi T, Ishii S, Salmon R, Kohiyama M. (1990). Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 46:35–8.
   PubMed Web of Science ®Google Scholar
• Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. (2001a). Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 61:7908–12.
   PubMed Web of Science ®Google Scholar
• Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM. (2001b). An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 98:9824–9.
   PubMed Web of Science ®Google Scholar
• Cioffi M, Vietri MT, Gazzerro P, Magnetta R, D’Auria A, Durante A, Nola E, Puca GA, Molinari AM. (2001). Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers. Lung Cancer 33:163–9.
   PubMedGoogle Scholar
• Crawford LV, Pim DC, Bulbrook RD. (1982). Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30:403–8.
   PubMed Web of Science ®Google Scholar
• Dobashi K, Sugio K, Osaki T, Oka T, Yasumoto K. (1997). Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg 114:339–46.
   Google Scholar
• Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K. (1997). K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 75:1125–30.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gronow M, Cuchacovich M, Llanos C, Urzua C, Gawdi G, Pizzo SV. (2006). Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res 66:11424–31.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Sancho JM, Aguilera O, Garcia JM, Pendas-Franco N, Pena C, Cal S, Garcia de Herreros A, Bonilla F, Munoz A. (2005). The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene 24:1098–103.
   PubMed Web of Science ®Google Scholar
• Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, Arand M, Ritter G, Old LJ, Knuth A. (1999). Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1: correlation with clinical events. Int J Cancer 84:506–10.
   PubMed Web of Science ®Google Scholar
• Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, de Fromentel CC, Preudhomme C, Fenaux P, Fournier G, Mangin P, Laurent-Puig P, Pelletier G, Schlumberger M, Desgrandchamps F, Le Duc A, Peyrat JP, Janin N, Bressac B, Soussi T et al. (1993). Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53:5872–6.
   PubMed Web of Science ®Google Scholar
• Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T. (1995). Serum p53 antibodies as early markers of lung cancer. Nat Med 1:701–2.
   PubMed Web of Science ®Google Scholar
• Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, Ginsberg RJ. (1995). Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120–129.
   PubMed Web of Science ®Google Scholar
• Mountain CF (1997). Revisions in the International System for Staging Lung Cancer. Chest 111:1710–17.
   PubMed Web of Science ®Google Scholar
• Nesterova MV, Johnson N, Cheadle C, Bates SE, Mani S, Stratakis CA, Khan IU, Gupta RK, Cho-Chung YS. (2006). Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res 66:8971–4.
   PubMedGoogle Scholar
• Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y, Sugano S, Akiyama T. (2004). DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 23:8520–6.
   PubMed Web of Science ®Google Scholar
• Osaki T, Mitsudomi T, Oyama T, Nakanishi R, Yasumoto K. (1995). Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest 108:157–62.
   Google Scholar
• Oyama T, Osaki T, Mitsudomi T, Ogawa R, Nakanishi R, Sugio K, Yasumoto K. (1998). p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. Int J Mol Med 1:823–6.
   Google Scholar
• Ozaki Y, Kontani K, Hanaoka J, Chano T, Teramoto K, Tezuka N, Sawai S, Fujino S, Yoshiki T, Okabe H, Ohkubo I. (2002). Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Cancer 95:1954–62.
   PubMedGoogle Scholar
• Parkin DM, Bray FI, Devesa SS. (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer 37 (Suppl. 8):S4–66.
   PubMed Web of Science ®Google Scholar
• Patil MA, Chua MS, Pan KH, Lin R, Lih CJ, Cheung ST, Ho C, Li R, Fan ST, Cohen SN, Chen X, So S. (2005). An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 24:3737–47.
   PubMed Web of Science ®Google Scholar
• Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E. (2006). Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 119:1728–31.
   PubMed Web of Science ®Google Scholar
• Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD, Jr., Epstein J, Kwak LW, Yi Q. (2007). Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110:1587–94.
   PubMed Web of Science ®Google Scholar
• Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, Sugarbaker DJ. (1995). Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 13:1265–79.
   Google Scholar
• Sugio K, Inoue T, Inoue K, Yaita H, Inuzuka S, Ishida T, Sugimachi K. (1993). Different site mutation of the K-ras gene in a patient with metachronous double lung cancers. Anticancer Res 13:2469–71.
   Google Scholar
• Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. (1992). Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52:2903–6.
   PubMed Web of Science ®Google Scholar
• Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. (2005). Autoantibody signatures in prostate cancer. N Engl J Med 353:1224–35.
   PubMed Web of Science ®Google Scholar
• Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. (1992). Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168–74.
   PubMed Web of Science ®Google Scholar
• Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer CG, Albrecht S, Von Schweinitz D, Pietsch T. (2003). Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms’ tumors. Lab Invest 83:429–34.
   PubMed Web of Science ®Google Scholar
• Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Kondo S, Nakamura Y, Daigo Y. (2007). Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 67:2517–25.
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Shimizu E, Ogura T, Sone S. (1996). Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int J Cancer 69:283–9.
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Shimizu E, Takeuchi E, Houchi H, Doi H, Bando H, Ogura T, Sone S. (1999). Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology 56:129–33.
   PubMed Web of Science ®Google Scholar
• Zweig MH, Campbell G. 1993. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561–77.
   PubMed Web of Science ®Google Scholar